National Instruments (NATI) Tops Q1 EPS by 7c, Miss on Revenues; Offers 2Q EPS Mid-Point Guidance Above Consensus
Get Alerts NATI Hot Sheet
Price: $59.98 --0%
Financial Fact:
Total cost of sales: 76.73M
Today's EPS Names:
SVBT, ZEO, OTLK, More
Financial Fact:
Total cost of sales: 76.73M
Today's EPS Names:
SVBT, ZEO, OTLK, More
Join SI Premium – FREE
National Instruments (NASDAQ: NATI) reported Q1 EPS of $0.26, $0.07 better than the analyst estimate of $0.19. Revenue for the quarter came in at $312 million versus the consensus estimate of $322.78 million.
Q1 2018 Highlights
- Revenue of $312 million, up 4 percent year over year
- GAAP gross margin of 76 percent and non-GAAP gross margin of 77 percent
- GAAP net income of $24 million, up 34 percent year over year
- Non-GAAP net income of $34 million, up 26 percent year over year
- Fully diluted GAAP EPS of $0.18 and fully diluted non-GAAP EPS of $0.26
- EBITDA of $46 million
- Cash and short-term investments of $415 million as of March 31, 2018
Guidance
- NI currently expects Q2 revenue to be in the range of $320 million to $350 million, which would be a new Q2 record at the midpoint.
- The company currently expects that GAAP fully diluted EPS will be in the range of $0.15 to $0.29 for Q2, with non-GAAP fully diluted EPS expected to be in the range of $0.23 to $0.37.
GUIDANCE:
National Instruments sees Q2 2018 EPS of $0.23-$0.37, versus the consensus of $0.24. National Instruments sees Q2 2018 revenue of $320-350 million, versus the consensus of $343.84 million.
For earnings history and earnings-related data on National Instruments (NATI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
- Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
- Acurx Pharmaceuticals (ACXP) Tops Q2 EPS by 4c
Create E-mail Alert Related Categories
Earnings, Guidance, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share